Tigecycline

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Staphylococcal Infections

Conditions

Staphylococcal Infections

Trial Timeline

Jan 1, 2007 → May 1, 2008

NCT ID

NCT00419991

About Tigecycline

Tigecycline is a approved stage product being developed by Pfizer for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00419991. Target conditions include Staphylococcal Infections.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (18)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01560143	Approved	Completed	Mar 1, 2012	May 1, 2012	Obesity
NCT01401023	Pre-clinical	Completed	Jul 1, 2011	Jul 1, 2013	Diarrhea
NCT01072539	Pre-clinical	Completed	May 1, 2010	Apr 1, 2015	Complicated Skin and Skin Structure Infections
NCT00827541	Pre-clinical	Completed	Aug 1, 2008	Dec 1, 2010	Intra-Abdominal Infections
NCT00575094	Phase 3	Completed	Nov 1, 2007	Mar 1, 2008	Community-Acquired Infections
NCT00419991	Approved	Completed	Jan 1, 2007	May 1, 2008	Staphylococcal Infections
NCT00406237	Phase 1	Completed	Dec 1, 2006	Mar 1, 2009	Liver Cirrhosis, Biliary
NCT00488488	Pre-clinical	Completed	Nov 1, 2006	Mar 1, 2010	Infection
NCT00376324	Phase 1	Completed	Sep 1, 2006	Oct 1, 2008	Healthy Subjects
NCT00488306	Approved	Completed	Aug 1, 2006	Aug 1, 2007	Abdominal Abscess
NCT00488761	Approved	Completed	Jul 1, 2006	Aug 1, 2007	Skin Diseases, Infectious
NCT00136201	Phase 3	Completed	Nov 1, 2005	Dec 1, 2006	Abdominal Abscess
NCT00205816	Phase 3	Completed	Jan 1, 2004	Nov 1, 2005	Bacterial Infections
NCT00079989	Phase 3	Completed	Dec 1, 2003	Nov 1, 2005	Gram-Negative Bacterial Infections
NCT00079885	Phase 3	Completed	Nov 1, 2003	Jul 1, 2005	Community Acquired Pneumonia
NCT00079976	Phase 3	Completed	Oct 1, 2003	Jun 1, 2005	Gram-Positive Bacterial Infections
NCT00081744	Phase 3	Completed	Nov 1, 2002	Aug 1, 2004	Gram-Positive Bacterial Infections
NCT00600600	Phase 2	Completed	Apr 1, 2002	Dec 1, 2010	Mycobacterium Abscessus Lung Disease

Competing Products

20 competing products in Staphylococcal Infections

See all competitors

Product	Company	Stage	Hype Score
Ceftobiprole	Johnson & Johnson	Phase 1	33
Ceftobiprole	Johnson & Johnson	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kg	Merck	Phase 3	77
V710 + Placebo	Merck	Phase 1	33
V710 + Comparator: Placebo	Merck	Phase 1	33
V710 (30 µg) with MAA + V710 (30 µg) without MAA	Merck	Phase 1	33
Daptomycin + Vancomycin	Merck	Approved	85
Daptomycin	Novartis	Approved	85
SA4Ag vaccine	Pfizer	Phase 1	32
Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine	Pfizer	Phase 2	51
linezolid (Zyvox)	Pfizer	Pre-clinical	22
Staphylococcus aureus 4-antigen vaccine + Placebo	Pfizer	Phase 2	51
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + Placebo	Pfizer	Phase 1	32
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo	Pfizer	Phase 1	32
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum ID	United Therapeutics	Phase 1	30
NDV-3 investigational vaccine	United Therapeutics	Phase 1	30
TD-1792 + Vancomycin	Theravance Biopharma	Phase 2	47
Ceftobiprole	Basilea Pharmaceutica	Phase 1	28
human lactoferrin peptide 1-11	AM-Pharma	Phase 1/2	33

Other Products from Pfizer